Genmab (GMAB) is bringing artificial intelligence into the lab, and investors are taking notice. Shares of the Danish biotechnology company climbed Wednesday after announcing a partnership with Anthropic, the AI firm behind the Claude language models.

How the AI Partnership Works

Genmab develops late-stage investigational antibody medicines targeting solid tumors and hematological malignancies. The company will deploy custom Claude-powered models to handle data processing, analysis, and document generation across its operations. The setup includes guardrails and human oversight, so it's not exactly handing the keys to the robots just yet.

The goal here is pretty straightforward: automate the tedious stuff so scientists can focus on actual science. "By reducing manual burden and enabling greater scale across our operations, our partnership with Anthropic will empower our teams to focus more time on high-value scientific and strategic work, with the goal of accelerating our path to patient impact," said Chief Medical Officer Tahamtan Ahmadi.

Market Reaction

Investors seem to like the move. GMAB shares rose 2.21% to $33.38 at the time of publication, according to market data.